For the patient living with a rare autoimmune condition, or the healthy adult curious whether their saliva sample could move a drug program forward, the path into clinical research has historically run through a clinic coordinator, a fax machine, and a lot of waiting. Joined Bio, a Lexington, Massachusetts company that came out of stealth in October 2025, is trying to redraw that path as a consumer marketplace, where participants share electronic medical record data, ship biosamples from home, and earn up to $250 per study they qualify for [Joined Bio, October 2025].
The bet
Joined Bio is building a two-sided marketplace. On one side sit participants, who connect their EMR data, complete surveys, and consent to provide biospecimens or join interventional trials. On the other sit researchers at sponsors, biotechs, and academic groups who need matched cohorts and physical samples. The company describes three core capabilities: secure integration of comprehensive EMR data, intelligent participation matching, and nationwide in-home collection [Joined Bio, October 2025].
The company has moved quickly on the supply side. In its first year it acquired BioSample Connect, a biospecimen procurement business that works with clinics, hospitals, and sample suppliers [Joined Bio]. In November 2025 it acquired DNAsimple, a participant-facing genetics sample company with an existing donor base [Joined Bio, November 2025; Crunchbase].
Why it could be big
Sponsors have spent the past five years under pressure from the FDA and EMA to enroll more representative trial populations, and the FDA's 2022 Diversity Action Plan guidance made cohort composition a regulatory question. Decentralized trial designs, accelerated during the pandemic, normalized the idea that consent, data capture, and even sample collection can happen outside a clinic. A platform that can deliver pre-consented, EMR-verified participants matched to a specific protocol, plus the logistics to collect a sample at home, is selling into a procurement problem that sponsors already have budget lines for.
The team and traction
Public LinkedIn profiles place Bill Arteca and Jill Mullan at Joined Bio [LinkedIn]. The company is headquartered in Lexington, Massachusetts and launched its platform publicly in October 2025 [Joined Bio, October 2025]. Two acquisitions inside roughly twelve months, BioSample Connect and DNAsimple, give the company an operating footprint that is unusual for a seed-stage healthtech [Joined Bio; Joined Bio, November 2025].
| Milestone | Date |
|---|---|
| Company founded | 2024 |
| BioSample Connect acquisition | 2025 |
| Platform public launch | October 2025 |
| DNAsimple acquisition | November 2025 |
The honest counterfactual
What bears will say is that patient-powered research marketplaces are a category with a long graveyard, and that the binding constraint has rarely been participant willingness. It has been sponsor procurement cycles, protocol-specific inclusion criteria that disqualify most volunteers, and the operational difficulty of turning a self-reported EMR connection into a regulator-grade dataset. What bulls answer, drawing on Joined Bio's own positioning, is that the company is not selling community, it is selling matched biospecimens and EMR-linked cohorts to researchers who already buy both categories today, and that the BioSample Connect acquisition gives it a running revenue motion into life-science buyers from day one [Joined Bio].
What to watch
The next twelve months will tell. Specific things worth tracking: whether Joined Bio discloses sponsor customers or named pharma partnerships, whether the in-home collection network reaches the geographic coverage the company has claimed, and whether participant retention on the DNAsimple base survives the rebrand.